Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.63 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.58 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.58 |
| ▸ | ITGAL | P20701 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051684 | 1.00 | GHSR (0.63) | GHSRITGB2ICAM1ITGALLTA4H | |
| SCHEMBL30610088 | 1.00 | GHSR (0.63) | GHSRITGB2ICAM1ITGALLTA4H | |
| SCHEMBL30052886 | 1.00 | GHSR (0.63) | GHSRITGB2ICAM1ITGALLTA4H | |
| SCHEMBL31609182 | 1.00 | GHSR (0.63) | GHSRITGB2ICAM1ITGALLTA4H | |
| SCHEMBL29533411 | 0.96 | GHSR (0.65) | GHSRITGB2ICAM1ITGALACE | |
| SCHEMBL31657628 | 0.95 | GHSR (0.58) | GHSRITGB2ICAM1ITGAL | |
| SCHEMBL29551519 | 0.95 | GHSR (0.58) | GHSRITGB2ICAM1ITGAL | |
| SCHEMBL21641802 | 0.92 | ITGB2 (0.67) | GHSRITGB2ICAM1ITGALACE | |
| SCHEMBL21641801 | 0.92 | ITGB2 (0.67) | GHSRITGB2ICAM1ITGALACE | |
| SCHEMBL29904257 | 0.92 | ITGB2 (0.67) | GHSRITGB2ICAM1ITGALACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | ANTISENSE THERAPEUTICS LTD (AU) | 2022-02-17 | — | — | US | claimed |
| US-20220047679-A1 | COMBINATION THERAPY | ANTISENSE THERAPEUTICS LTD (AU) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | GHSR, GHRHR, IGF1R | GHSR 1/4885ITGB2 3225/4885ICAM1 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.